BridgeBio Pharma To Share Long-Term Efficacy, Safety Data In Participants With ATTR-CM From Its Phase 3 Trial Of Acoramidis At American College of Cardiology Annual Scientific Sessions & Expo

BridgeBio Pharma, Inc. (Nasdaq: BBIO) will present long-term efficacy and safety data from its Phase 3 trial of acoramidis for ATTR-CM at the American College of Cardiology Annual Scientific Sessions & Expo on March 28-30, 2026. The presentation will include findings from the open-label extension trial, along with three posters on additional data and real-world survey results.